FULVESTRANT TEVA 250 mg, solution for injection in a pre-filled syringe 2 syringes of 5 ml
Active ingredients: Fulvestrant
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injection2 syringes of 5 mlintramusculaire
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- FULVESTRANT TEVA 250 mg, solution injectable en seringue préremplie
- Pharmaceutical form
- solution injectable
- Route of administration
- intramusculaire
- Presentation description
- 2 seringue(s) préremplie(s) en verre de 5 ml avec un piston polypropylène, munies d'un connecteur Luer-Lock avec 2 aiguilles protégées
- Marketing authorisation holder
- TEVA SANTE
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 11 Jan 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63053767CIP73010300CIP133400930103005Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| FULVESTRANTsolution | 250 mg · une seringue préremplie de 5 mL | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.